Glybenclamide: An antidiabetic with in vivo antithrombotic activity

European Journal of Pharmacology

Volumn 649, Issue 1-3, 2010, Pages 249-254

  Ting, Harold J ^a   Khasawneh, Fadi T ^a  

^a WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Antagonist; Antiplatelet agent; Antithrombotic agent; Drug repurposing; Platelet activation; Thrombosis; Thromboxane A2 receptor

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; ADENOSINE DIPHOSPHATE; GLIBENCLAMIDE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; THROMBIN RECEPTOR ACTIVATING PEPTIDE 4; THROMBOXANE A2 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; FEMALE; HEMOSTASIS; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOSIS PREVENTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; ARACHIDONIC ACID; BLEEDING TIME; CAROTID ARTERY THROMBOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG REPOSITIONING; FIBRINOLYTIC AGENTS; GLYBURIDE; HEMOSTASIS; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED C57BL; OSMOLAR CONCENTRATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, THROMBOXANE; THROMBOEMBOLISM; THROMBOSIS; TIME FACTORS;

EID: 78049250380     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.09.009     Document Type: Article

References (50)

1. Ablooglu A.J., Kang J., Petrich B.G., Ginsberg M.H., Shattil S.J. Antithrombotic effects of targeting alphaIIbbeta3 signaling in platelets. Blood 2009, 113:3585-3592.
2. Aronson J.K. Old drugs-new uses. Br. J. Clin. Pharmacol. 2007, 64:563-565.
3. Badole S.L., Patel N.M., Thakurdesai P.A., Bodhankar S.L. Interaction of aqueous extract of Pleurotus pulmonarius (Fr.) Quel-Champ. with Glyburide in alloxan induced diabetic mice. Evid. Based Complement Altern. Med. 2008, 5:159-164.
4. Baglia F.A., Shrimpton C.N., Emsley J., Kitagawa K., Ruggeri Z.M., Lopez J.A., Walsh P.N. Factor XI interacts with the leucine-rich repeats of glycoprotein Ibalpha on the activated platelet. J. Biol. Chem. 2004, 279:49323-49329.
5. Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962, 194:927-929.
6. Brisson C., Azorsa D.O., Jennings L.K., Moog S., Cazenave J.P., Lanza F. Co-localization of CD9 and GPIIb-IIIa (alpha IIb beta 3 integrin) on activated platelet pseudopods and alpha-granule membranes. Histochem. J. 1997, 29:153-165.
7. Butkus A., Skrinska V.A., Schumacher O.P. Thromboxane production and platelet aggregation in diabetic subjects with clinical complications. Thromb. Res. 1980, 19:211-223.
8. Chong C.R., Sullivan D.J. New uses for old drugs. Nature 2007, 448:645-646.
9. Clarke R.J., Mayo G., Price P., FitzGerald G.A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med. 1991, 325:1137-1141.
10. Cohen F.J. Macro trends in pharmaceutical innovation. Nat. Rev. Drug Discov. 2005, 4:78-84.
11. Davi G., Patrono C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357:2482-2494.
12. Davi G., Rini G.B., Averna M., Novo S., Di Fede G., Pinto A., Notarbartolo A., Strano A. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. Thromb. Res. 1982, 26:359-370.
13. Del Guerra S., D'Aleo V., Lupi R., Masini M., Bugliani M., Boggi U., Filipponi F., Marchetti P. Effects of exposure of human islet beta-cells to normal and high glucose levels with or without gliclazide or glibenclamide. Diab. Metab. 2009, 35:293-298.
14. Dessi P. Basic pharmacological research on the hypoglycemic action of N-4-[beta-(2-methoxy-5-chlorbenzamide)-ethyl]-benzosulfonyl-N'-cyclohexylu rea (Glybenclamide). Acta Diabetol. Lat. 1969, 6:206-221.
15. DiMasi J.A., Hansen R.W., Grabowski H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 2003, 22:151-185.
16. Du X. Signaling and regulation of the platelet glycoprotein Ib-IX-V complex. Curr. Opin. Hematol. 2007, 14:262-269.
17. Fenton D.A., Wilkinson J.D. Topical minoxidil in the treatment of alopecia areata. Br. Med. J. (Clin. Res. Ed.) 1983, 287(6398):1015-1017.
18. Ghali N.I., Kattelman E.J., Hung S.C., Schnorf K.E., Le Breton G.C., Venton D.L. Synthesis of [17, 18-3H] trans-13-azaprostanoic acid. A labeled probe for the PGH2/TXA2 receptor. Prostaglandins 1984, 27:865-876.
19. Gu K., Cowie C.C., Harris M.I. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diab. Care 1998, 21:1138-1145.
20. Halushka P.V., Mais D.E., Mayeux P.R., Morinelli T.A. Thromboxane, prostaglandin and leukotriene receptors. Annu. Rev. Pharmacol. Toxicol. 1989, 29:213-239.
21. Hirata M., Hayashi Y., Ushikubi F., Yokota Y., Kageyama R., Nakanishi S., Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature 1991, 349:617-620.
22. Israeli A., Matzner Y., Or R., Raz I. Glibenclamide causing thrombocytopenia and bleeding tendency: case reports and a review of the literature. Klin. Wochenschr. 1988, 66:223-224.
23. Jin B., Hopfinger A.J. A proposed common spatial pharmacophore and the corresponding active conformations of some TxA2 receptor antagonists. J. Chem. Inf. Comput. Sci. 1994, 34:1014-1021.
24. Kim S.O., Lim C.T., Lam S.C., Hall S.E., Komiotis D., Venton D.L., Le Breton G.C. Purification of the human blood platelet thromboxane A2/prostaglandin H2 receptor protein. Biochem. Pharmacol. 1992, 43:313-322.
25. Landis R.C. Protease activated receptors: clinical relevance to hemostasis and inflammation. Hematol. Oncol. Clin. North Am. 2007, 21:103-113.
26. Le Breton G.C., Venton D.L., Enke S.E., Halushka P.V. 13-Azaprostanoic acid: a specific antagonist of the human blood platelet thromboxane/endoperoxide receptor. Proc. Natl. Acad. Sci. USA 1979, 76:4097-4101.
27. Lee J.J., Jin Y.R., Yu J.Y., Munkhtsetseg T., Park E.S., Lim Y., Kim T.J., Pyo M.Y., Hong J.T., Yoo H.S., Kim Y., Yun Y.P. Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug. Atherosclerosis 2009, 206:375-382.
28. Lee P.E., Meneilly G.S. The effect of octreotide on glucose and insulin levels in a patient with type 2 diabetes on glibenclamide. Diab. Metab. 1999, 25:347-349.
29. Lima R., Tardim J.C., Barros M.E., Boim M.A. Role of ATP-sensitive potassium channels in normal and hypertension-associated pregnancy in rats. Clin. Exp. Pharmacol. Physiol. 2006, 33:780-786.
30. Lumley P., White B.P., Humphrey P.P. GR32191, a highly potent and specific thromboxane A2 receptor blocking drug on platelets and vascular and airways smooth muscle in vitro. Br. J. Pharmacol. 1989, 97:783-794.
31. Maia J.L., Lima-Junior R.C., Melo C.M., David J.P., David J.M., Campos A.R., Santos F.A., Rao V.S. Oleanolic acid, a pentacyclic triterpene attenuates capsaicin-induced nociception in mice: possible mechanisms. Pharmacol. Res. 2006, 54:282-286.
32. Marjanovic J.A., Li Z., Stojanovic A., Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J. Biol. Chem. 2005, 280:37430-37438.
33. Meijer K., Schulman S. Determinants of bleeding risk in patients on antithrombotic and antifibrinolytic drugs. Semin. Thromb. Hemost. 2008, 34:762-771.
34. Nicolaou K.C., Magolda R.L., Smith J.B., Aharony D., Smith E.F., Lefer A.M. Synthesis and biological properties of pinane-thromboxane A2, a selective inhibitor of coronary artery constriction, platelet aggregation, and thromboxane formation. Proc. Natl. Acad. Sci. USA 1979, 76:2566-2570.
35. Oates J.A., FitzGerald G.A., Branch R.A., Jackson E.K., Knapp H.R., Roberts L.J. Clinical implications of prostaglandin and thromboxane A2 formation (2). N. Engl. J. Med. 1988, 319:761-767.
36. Ogletree M.L. Overview of physiological and pathophysiological effects of thromboxane A2. Fed. Proc. 1987, 46:133-138.
37. Ogletree M.L., Harris D.N., Greenberg R., Haslanger M.F., Nakane M. Pharmacological actions of SQ 29, 548, a novel selective thromboxane antagonist. J. Pharmacol. Exp. Ther. 1985, 234:435-441.
38. Patrono C. Aspirin as an antiplatelet drug. N. Engl. J. Med. 1994, 330:1287-1294.
39. Patrono C., Ciabattoni G., Davi G. Thromboxane biosynthesis in cardiovascular diseases. Stroke 1990, 21:IV130-IV133.
40. Patscheke H., Stegmeier K., Muller-Beckmann B., Sponer G., Staiger C., Neugebauer G. Inhibitory effects of the selective thromboxane receptor antagonist BM 13.177 on platelet aggregation, vasoconstriction and sudden death. Biomed. Biochim. Acta 1984, 43:S312-318.
41. Pusch G., Feher G., Kotai K., Tibold A., Gasztonyi B., Feher A., Papp E., Lupkovics G., Szapary L. Aspirin resistance: focus on clinical endpoints. J. Cardiovasc. Pharmacol. 2008, 52:475-484.
42. Reilly M., Fitzgerald G.A. Cellular activation by thromboxane A2 and other eicosanoids. Eur. Heart J. 1993, 14(Suppl K):88-93.
43. Sampaio E.P., Hernandez M.O., Carvalho D.S., Sarno E.N. Management of erythema nodosum leprosum by thalidomide: thalidomide analogues inhibit M. leprae-induced TNFalpha production in vitro. Biomed. Pharmacother. 2002, 56:13-19.
44. Schlansky B., Hwang J.H. Prevention of nonsteroidal anti-inflammatory drug-induced gastropathy. J. Gastroenterol. 2009, 44(Suppl 19):44-52.
45. Shi M.Z., Feng J.G., Zheng J.J. A comparison between glibenclamide and glipizide in the treatment of type II diabetes. Zhonghua Nei Ke Za Zhi 1991, 30(94-97):126.
46. Tanaka T., Sato R., Kurimoto T. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. Eur. J. Pharmacol. 2000, 401:413-418.
47. Thom T., Haase N., Rosamond W., Howard V.J., Rumsfeld J., Manolio T., Zheng Z.J., Flegal K., O'Donnell C., Kittner S., Lloyd-Jones D., Goff D.C., Hong Y., Adams R., Friday G., Furie K., Gorelick P., Kissela B., Marler J., Meigs J., Roger V., Sidney S., Sorlie P., Steinberger J., Wasserthiel-Smoller S., Wilson M., Wolf P. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006, 113:e85-151.
48. Thomas D.W., Mannon R.B., Mannon P.J., Latour A., Oliver J.A., Hoffman M., Smithies O., Koller B.H., Coffman T.M. Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Invest. 1998, 102:1994-2001.
49. Ting H.J., Murray W.J., Khasawneh F.T. Repurposing an old drug for a new use: glybenclamide exerts antiplatelet activity by interacting with the thromboxane A(2) receptor. Acta Pharmacol. Sin. 2010, 31:150-159.
50. Zarch A.V., Toroudi H.P., Soleimani M., Bakhtiarian A., Katebi M., Djahanguiri B. Neuroprotective effects of diazoxide and its antagonism by glibenclamide in pyramidal neurons of rat hippocampus subjected to ischemia-reperfusion-induced injury. Int. J. Neurosci. 2009, 119:1346-1361.